吡柔比星与丝裂霉素膀胱灌注化疗防治腺性膀胱炎术后复发的效果比较  

Pirarubicin Intravesical Chemotherapy With Mitomycin Prevention of Postoperative Inflammation Gland Bladder Recurrence

作　　者：宋军锋 

机构地区：[1]河南省禹州市人民医院,461670

出　　处：《中国继续医学教育》2015年第6期244-245,共2页China Continuing Medical Education

摘　　要：目的：比较吡柔比星与丝裂霉素膀胱灌注化疗防治腺性膀胱炎术后复发的效果。方法回顾性分析2012年10月～2013年10月本院收治的96例腺性膀胱炎患者的临床资料，按照随机数字表法分为两组，每组48例，比较两组患者疗效、不良反应情况。结果观察组总有效率89.58%高于对照组的72.92%，且复发率（6.25%）低于对照组（22.92%），差异均具统计学意义（P＜0.05）。结论吡柔比星膀胱灌注化疗防治腺性膀胱炎术后复发的效果优于丝裂霉素。ObjectiveTo Compare Pirarubicin with intravesical mitomycin chemotherapy for preventing the recurrence of bladder inflammation after glandular effect.Methods A retrospective analysis of clinical data in October 2012～October 2013 our hospital 96 cases of glandular inflammation in patients with bladder, according to the random number table is divided into two groups, 48 cases, two groups were compared the efifcacy, adverse reactions situation.Results Observation group was 89.58%higher than the efifciency of 72.92%, and the recurrence rate was 6.25%lower than the 22.92% in the control group, the difference was statistically significant （P〈0.05）. ConclusionTHP intravesical chemotherapy for preventing recurrence of bladder inflammation gland surgery better than mitomycin.

关 键 词：吡柔比星 丝裂霉素 灌注化疗 腺性膀胱炎 

分 类 号：R694.3[医药卫生—泌尿科学]